Clinical Trial Provides Preliminary Evidence Of A Cure For Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) And Long Covid

Cortene Inc. announces publication of its InTiME clinical trial in which a short subcutaneous infusion of its experimental drug, CT38, achieved sustained symptom improvement in ME/CFS.  The company intends to test CT38 in Long Covid, the post-acute stage of COVID-19 infection, which is considered by many to be the latest trigger for ME/CFS.

Cortene believes the CRFR2 pathway is upregulated and therefore overactive, leading to the wide variety of symptoms in ME/CFS.  “The conventional approach would be to block the overactive pathway,” said Sanjay Chanda, PhD, Cortene’s Chief Development Officer.  “Instead, our counterintuitive approach seeks to overstimulate CRFR2, causing it to downregulate, without the need for chronic treatment.”

To read the rest of this story, click on the link below:

https://www.prnewswire.co.uk/news-releases/clinical-trial-provides-preliminary-evidence-of-a-cure-for-myalgic-encephalomyelitis-chronic-fatigue-syndrome-me-cfs-and-long-covid-876403518.html

Leave a Reply

The York ME Community © 2015
Powered by Live Score & Live Score App